Benzamide, 2-(6-azaspiro[2.5]oct-6-yl)-N-[3-[[(1,1-dimethylethyl)amino]sulfonyl]phenyl]-4-[(methylsulfonyl)amino]-

KIF18A-IN-2 is a potent KIF18A inhibitor (IC50=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer[1]. KIF18A-IN-2 (compound 23) (100 mg/kg; i.p., single) exhibits a significant and sustained pharmacodynamic response, increasing the number of mitotic cells (pH3 positive cells) in tumor tissues for up to 24 hours[1].Pharmacokinetic Parameters of KIF18A-IN-2 in female CD-1 mice[1]. IP (100 mg/kg) Cmax (μM)12.6AUC0-24 (μM.h)147 C24h (μM)2.9PPB (fu)0.007

[1]. Tamayo NA, et al. Targeting the Mitotic Kinesin KIF18A in Chromosomally Unstable Cancers: Hit Optimization Toward an In Vivo Chemical Probe. J Med Chem. 2022;65(6):4972-4990.